U.S. markets closed

ARYA Sciences Acquisition Corp. (ARYAU)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
19.60-0.40 (-2.00%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close20.00
Open19.69
Bid17.71 x 1400
Ask0.00 x 1100
Day's Range19.50 - 20.00
52 Week Range10.45 - 22.00
Volume1,038
Avg. Volume8,641
Market Cap329.082M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Arya Sciences Acquisition Corp. Shareholders Approve Business Combination Transaction with Immatics
      Business Wire

      Arya Sciences Acquisition Corp. Shareholders Approve Business Combination Transaction with Immatics

      Arya Sciences Acquisition Corp. (NASDAQ: ARYA or "Arya"), a special purpose acquisition company sponsored by Perceptive Advisors, and Immatics Biotechnologies GmbH ("Immatics"), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies, today announced that its respective shareholders approved the business combination between Arya and Immatics announced on March 17, 2020. None of Arya’s shareholders redeemed their shares in connection with the ARYA shareholder approval. The respective boards of directors of both Arya and Immatics had previously approved the business combination.

    • STOCKHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Arya Sciences Acquisition Corp. - ARYA
      PR Newswire

      STOCKHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Arya Sciences Acquisition Corp. - ARYA

      Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating Arya Sciences Acquisition Corp. ("Arya Sciences" or the "Company") (NasdaqGS: ARYA) relating its combination with Immatics B.V., a Netherlands private limited company. Under the terms of the agreement, each outstanding share of Arya common stock, will be automatically exchanged for one share of the newly formed company, Immatics N.V.